WSO - March 2024 - 342

1206680
WSO
International Journal of StrokeHarbison et al.
Research
Changes in anticoagulation practice
in subjects admitted with stroke
associated with atrial fibrillation,
following introduction of direct oral
anticoagulants over 2013-2021
Joseph Harbison1,2,3 , Joan McCormack1, Olga Brych1 , Ronan
Collins1,2, Niamh O'Connell4, Mary Randles2, Cormac Kennedy5,
Peter J Kelly6,7 and Tim Cassidy1,8
Abstract
Background: The adoption of direct oral anticoagulants (DOACs) has changed practice in prevention of stroke in
atrial fibrillation (AF). We used Irish data national data on stroke and anticoagulation therapy over 9 years to investigate
changes in anticoagulation practice and potential consequences on stroke prevalence and thrombolysis.
Methods: AF, anticoagulation, thrombolysis, and stroke data from the Irish National Audit of Stroke (INAS) 2013-2021
were reviewed. The proportion of patients with ischemic stroke (IS) and intracerebral hemorrhage (IH) with known
AF admitted on anticoagulation was determined. Effects on age distribution in the population and thrombolysis practice
were assessed.
Results: AF data were available on 34,630 of 35,241 individuals (98.3%) included in INAS; median age was 74 years and
56% were male. AF was found in 10,016 (28.9%, 9059 IS, 957 IH). 6313 had known AF prior to stroke (63.1%). The
proportion all total IS due to AF decreased by 15.3% (31.3%−26.5%, chi-square = 24.6, p < 0.0001). The proportion of IH
did not change significantly (21.6%-20.2%, chi-square = 1.8, p = 0.18). Over the 9 years, 3875 (38.6%) of the subjects with
AF were recorded as receiving anticoagulants at admission. In 2013, 4.4% of AF-associated strokes were admitted on a
DOAC and 21.4% on warfarin; by 2021, 44.1% were receiving a DOAC and 6.2% warfarin. There was a strong inverse
correlation between the proportion of anticoagulated stroke patients and the total proportion of AF-associated strokes
over time (r = −0.82, p = 0.006). In contrast, no correlation was found between increasing DOAC usage and IH (r = 0.14,
p = 0.71). Increased anticoagulation usage correlated with a reduction in patients ⩾ 80 years (r = −0.83, p = 0.006) and also
correlated with a relative reduction of 30.1% in subjects thrombolysed <4 h from onset (r = −0.89, p = 0.001)
Conclusion: DOACs have led to increased use of anticoagulation, but warfarin use fell by two-thirds. There has been a
reduction in the proportion of AF-associated IS without a noticeable increase in IH. Increased anticoagulation correlated
with reduced numbers of strokes in those >80 years and in the proportion of patients thrombolysed.
Keywords
Anticoagulation, stroke, population study, audit
Received: 19 July 2023; accepted: 15 September 2023
1Irish National Audit of Stroke, National Office of Clinical Audit, Dublin, Ireland
2Department of Medical Gerontology, School of Medicine, Trinity College Dublin, The University of Dublin, Dublin, Ireland
3Mercer's Institute for Successful Ageing, St. James's Hospital, Dublin, Ireland
4National Coagulation Centre, St. James's Hospital, Dublin, Ireland
5Department of Pharmacology & Therapeutics, School of Medicine, Trinity College Dublin, The University of Dublin, Dublin, Ireland
6Department of Neurology, University College Dublin, Dublin, Ireland
7Institute of Neurology, The Mater Hospital, Dublin, Ireland
8Acute Stroke Service, St. Vincent's University Hospital, Dublin, Ireland
Corresponding author:
Joseph Harbison, Mercer's Institute for Successful Ageing, St. James's Hospital, Dublin D08 W9RT, Ireland.
Email: jharbiso@tcd.ie
International Journal of Stroke, 19(3)
International Journal of Stroke
2024, Vol. 19(3) 342 -347
© 2023 World Stroke Organization
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/17474930231206680
journals.sagepub.com/home/wso
https://doi.org/10.1177/17474930231206680
http://www.sagepub.com/journals-permissions https://www.doi.org/10.1177/17474930231206680 http://journals.sagepub.com/home/wso

WSO - March 2024

Table of Contents for the Digital Edition of WSO - March 2024

Contents
WSO - March 2024 - Cover1
WSO - March 2024 - Cover2
WSO - March 2024 - 245
WSO - March 2024 - Contents
WSO - March 2024 - 247
WSO - March 2024 - 248
WSO - March 2024 - 249
WSO - March 2024 - 250
WSO - March 2024 - 251
WSO - March 2024 - 252
WSO - March 2024 - 253
WSO - March 2024 - 254
WSO - March 2024 - 255
WSO - March 2024 - 256
WSO - March 2024 - 257
WSO - March 2024 - 258
WSO - March 2024 - 259
WSO - March 2024 - 260
WSO - March 2024 - 261
WSO - March 2024 - 262
WSO - March 2024 - 263
WSO - March 2024 - 264
WSO - March 2024 - 265
WSO - March 2024 - 266
WSO - March 2024 - 267
WSO - March 2024 - 268
WSO - March 2024 - 269
WSO - March 2024 - 270
WSO - March 2024 - 271
WSO - March 2024 - 272
WSO - March 2024 - 273
WSO - March 2024 - 274
WSO - March 2024 - 275
WSO - March 2024 - 276
WSO - March 2024 - 277
WSO - March 2024 - 278
WSO - March 2024 - 279
WSO - March 2024 - 280
WSO - March 2024 - 281
WSO - March 2024 - 282
WSO - March 2024 - 283
WSO - March 2024 - 284
WSO - March 2024 - 285
WSO - March 2024 - 286
WSO - March 2024 - 287
WSO - March 2024 - 288
WSO - March 2024 - 289
WSO - March 2024 - 290
WSO - March 2024 - 291
WSO - March 2024 - 292
WSO - March 2024 - 293
WSO - March 2024 - 294
WSO - March 2024 - 295
WSO - March 2024 - 296
WSO - March 2024 - 297
WSO - March 2024 - 298
WSO - March 2024 - 299
WSO - March 2024 - 300
WSO - March 2024 - 301
WSO - March 2024 - 302
WSO - March 2024 - 303
WSO - March 2024 - 304
WSO - March 2024 - 305
WSO - March 2024 - 306
WSO - March 2024 - 307
WSO - March 2024 - 308
WSO - March 2024 - 309
WSO - March 2024 - 310
WSO - March 2024 - 311
WSO - March 2024 - 312
WSO - March 2024 - 313
WSO - March 2024 - 314
WSO - March 2024 - 315
WSO - March 2024 - 316
WSO - March 2024 - 317
WSO - March 2024 - 318
WSO - March 2024 - 319
WSO - March 2024 - 320
WSO - March 2024 - 321
WSO - March 2024 - 322
WSO - March 2024 - 323
WSO - March 2024 - 324
WSO - March 2024 - 325
WSO - March 2024 - 326
WSO - March 2024 - 327
WSO - March 2024 - 328
WSO - March 2024 - 329
WSO - March 2024 - 330
WSO - March 2024 - 331
WSO - March 2024 - 332
WSO - March 2024 - 333
WSO - March 2024 - 334
WSO - March 2024 - 335
WSO - March 2024 - 336
WSO - March 2024 - 337
WSO - March 2024 - 338
WSO - March 2024 - 339
WSO - March 2024 - 340
WSO - March 2024 - 341
WSO - March 2024 - 342
WSO - March 2024 - 343
WSO - March 2024 - 344
WSO - March 2024 - 345
WSO - March 2024 - 346
WSO - March 2024 - 347
WSO - March 2024 - 348
WSO - March 2024 - 349
WSO - March 2024 - 350
WSO - March 2024 - 351
WSO - March 2024 - 352
WSO - March 2024 - 353
WSO - March 2024 - 354
WSO - March 2024 - 355
WSO - March 2024 - 356
WSO - March 2024 - 357
WSO - March 2024 - 358
WSO - March 2024 - 359
WSO - March 2024 - 360
WSO - March 2024 - 361
WSO - March 2024 - 362
WSO - March 2024 - 363
WSO - March 2024 - 364
WSO - March 2024 - 365
WSO - March 2024 - 366
WSO - March 2024 - 367
WSO - March 2024 - 368
WSO - March 2024 - 369
WSO - March 2024 - 370
WSO - March 2024 - 371
WSO - March 2024 - 372
WSO - March 2024 - Cover3
WSO - March 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com